Rachel Layman
M.D. Anderson Cancer Center · Ohio State University · Ohio State University Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rachel Layman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:11 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05243641 · Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis TestM.D. Anderson Cancer Center · terminated · Metastatic Breast Cancer, Breast Cancer · principal investigator
- Ph1/Ph2NCT03101748 · Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerM.D. Anderson Cancer Center · terminated · Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma · principal investigator
- N/ANCT01640340 · Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)Ohio State University Comprehensive Cancer Center · completed · Malignant Neoplasm · principal investigator
- Ph1/Ph2NCT00834678 · Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast CancerOhio State University Comprehensive Cancer Center · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:11 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial.J Clin Oncol · 2014268 citationsRCR 9.4
- Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.Clin Cancer Res · 2013229 citationsRCR 6.0
- Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.J Clin Oncol · 2025112 citationsRCR 23.8
- Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial.Psychooncology · 2015101 citationsRCR 4.3
- Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.Clin Cancer Res · 201663 citationsRCR 1.9
- Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.Nat Med · 202454 citationsRCR 5.9
- 47 citationsRCR 5.0
- Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.Cancer Chemother Pharmacol · 201338 citationsRCR 1.0
- 38 citationsRCR 1.7
- Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.Breast Cancer Res Treat · 201833 citationsRCR 1.8